Long-Chain MUFA Agent for Visceral Fat Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic syndrome primarily rely on food restrictions and pharmaceutical drugs, with a need for effective, naturally derived agents that target the accumulation of visceral fat and associated metabolic issues.
Innovation Solution
A dietary agent comprising MUFA (monounsaturated fatty acids) with 20 or 22 carbons, or their salts or esters, in a concentration of at least 50% by weight, derived from fish oils such as saury or Alaska pollock oil, which are used to reduce white adipose tissue, blood glucose, and cholesterol levels, and promote energy metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (food restrictions and pharmaceutical drugs) are used for metabolic syndrome, then individual symptoms can be treated, but the accumulation of visceral fat and associated metabolic issues persist and multiple medications are required
Solution Approach 1:
The patent extracts and isolates the specific functional component (long-chain MUFAs with 20 or 22 carbons) from the complex fish oil mixture to create a targeted treatment that addresses the root cause of metabolic syndrome - visceral fat accumulation - rather than treating multiple symptoms separately with different drugs
Solution Approach 2:
The patent specifies precise parameter ranges for the fatty acid composition (long-chain MUFAs with 20 or 22 carbons at specific concentrations) to optimize the ameliorative effect on metabolic syndrome, transforming the general fish oil supplement into a standardized therapeutic agent with defined efficacy
2Reliability
If fish oil supplements are used to provide long-chain MUFAs, then blood glucose values can be reduced, but the specific efficacy depends on carbon number and double bond configuration which are not standardized
Solution Approach 1:
The patent establishes specific parameter specifications for the fatty acid composition, defining that the fish oil must contain long-chain MUFAs with 20 or 22 carbons in predetermined amounts, thereby standardizing the product to ensure consistent blood glucose reduction effects across different batches
Solution Approach 2:
The patent emphasizes the importance of specific local characteristics within the fatty acid structure (carbon number 20 or 22, specific double bond positions) that determine the biological activity, ensuring that only fatty acids with these precise local qualities are included in the therapeutic composition
3Object-affected harmful factors
If natural substances are used to treat metabolic syndrome, then safety is improved, but the efficacy and consistency of natural variation in fish oil composition may be insufficient
Solution Approach 1:
The patent extracts the specific therapeutic components (long-chain MUFAs with 20 or 22 carbons) from the natural fish oil source, concentrating the active ingredients while removing variable or inactive components, thus maintaining the natural safety profile while ensuring consistent therapeutic efficacy
Solution Approach 2:
The patent creates a standardized composite composition from natural fish oil sources by defining specific ranges for long-chain MUFAs and other fatty acid components, combining the safety of natural origin with the consistency of standardized formulation
Data Source
Figure 1
Figure 2A~2D
Figure 3~4B
AI summary
An object of the present invention is to provide an ameliorating agent for improving metabolic syndrome. The inventors focused on the efficacy of MUFA, which is richly contained in saury oil, on physiological actions. As a result of repeated research, the inventors discovered that C20:1 and C22:1 free fatty acids have an ameliorative effect on metabolic syndrome, and achieved the present invention. The present invention provides a metabolic syndrome ameliorating agent comprising a MUFA having 22 carbons. In addition, the present invention provides a metabolic syndrome ameliorating agent comprising a MUFA having 22 carbons and a MUFA having 20 carbons. Furthermore, the present invention provides a metabolic syndrome ameliorating agent comprising a fish oil including a MUFA having 22 carbons and a MUFA having 20 carbons.